UCLA ’s Dennis Slamon awarded Sjöberg Prize for pioneering cancer research

Dr. Dennis Slamon, director of the Revlon/UCLA Women ’s Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation. Honored for his groundbreaking research that led to the development of successful targeted cancer therapies, Slamon shares the award with D r. Brian Druker of Oregon Health&Science University.The Sj öberg Prize has been awarded annually since 2016 to recognize outstanding cancer research. The honor carries a prize of $1 million — $100,000 as award money and $900,000 to fund future research — which Slamon and Druker will split equally. Among the previous honorees is Dr. James Allison of the University of Texas MD Anderson Cancer Center, who went on to win the Nobel Prize in physiology or medicine for 2018.Slamon, who also is director of clinical and translational research at the  UCLA Jonsson Comprehensive Cancer Center, was selected for his“groundbreaking contributions to the clinical development of targeted therapy directed against genetic aberrations in cancer,” according to the Royal Swedish Academy. He will present a lecture at the Karolinska Institute in Stockholm on March 29 and receive the award from Carl XVI Gustaf the king of Sweden, in a March 31 ceremony in that city.Slamon ’s research led to the development of the breast cancer drug trastuzumab (Herceptin), which since its introduction in 1998, ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news

Related Links:

Publication date: Available online 22 June 2019Source: Journal of Geriatric OncologyAuthor(s): Etienne Brain, Philippe Caillet, Nienke de Glas, Laura Biganzoli, Karis Cheng, Lissandra Dal Lago, Hans WildiersAbstractHER2-positive (HER2+) breast cancer (BC) affects older women nearly as frequently as younger ones. Many older patients have cardiovascular comorbidity and risk greater toxicity from therapy. Treatment therefore requires careful consideration, especially since trials include few patients over 65 and so provide limited guidance. A multidisciplinary task force of the International Society of Geriatric Oncology cond...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Objectives: The contribution of tumor subtypes (TS) in each stage of breast cancer with the use of contemporary therapies is unclear. The aim of this study was to analyze differences in overall survival (OS) by TS according to stage compared with other factors. Materials and Methods: We evaluated women with breast cancer diagnosed between 2010 and 2013 with known estrogen receptor and progesterone receptor (together hormone receptor [HR]) status and human epidermal growth factor receptor 2 (HER2) status reported to the SEER program. Patient characteristics were compared between TS. Univariate and multivariate analyses...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Breast Source Type: research
The new approval is for patients with germline BRCA-mutated, HER2 negative locally advanced or metastatic breast cancer.International Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
ita Diterpenoid alkaloids are isolated from plants of the genera Aconitum, Delphinium, and Garrya (Ranunculaceae) and classified according to their chemical structures as C18-, C19- or C20-diterpenoid alkaloids. The extreme toxicity of certain compounds, e.g., aconitine, has prompted a thorough investigation of how structural features affect their bioactivities. Therefore, natural diterpenoid alkaloids and semi-synthetic alkaloid derivatives were evaluated for cytotoxic effects against human tumor cells [A549 (lung carcinoma), DU145 (prostate carcinoma), MDA-MB-231 (triple-negative breast cancer), MCF-7 (estrogen recep...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
Dr Harold Burstein highlights ASCO oral presentations on early breast cancer, featuring neoadjuvant therapy in HER2-positive disease and updated data from the TAILORx study in HR-positive disease.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news
Condition:   Metastatic Breast Cancer Intervention:   Drug: Pyrotinib combine with SHR6390 Sponsors:   Sun Yat-sen University;   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Goller SS, Markert UR, Fröhlich K Abstract Breast cancer is one of the most common malignancies which appear during pregnancy. Since women are increasingly not giving birth until they are at a more advanced age, it can be assumed that the incidence of pregnancy-related breast cancers will continue to increase in the future. Because of pregnancy-induced changes and conservative diagnosis, these carcinomas are frequently not detected until they are at an advanced stage and thus generally require systemic adjuvant therapy. The available data on optimal chemotherapeutic management are limited. Particularl...
Source: Geburtshilfe und Frauenheilkunde - Category: OBGYN Tags: Geburtshilfe Frauenheilkd Source Type: research
Condition:   Metastatic Breast Cancer Intervention:   Drug: Pyrotinib combine with SHR6390 Sponsors:   Sun Yat-sen University;   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: There does not exist an optimal treatment sequence for hormone-receptor-positive, her2-negative advanced breast cancer. However, after review of literature, a reasonable approach may be starting with tamoxifen, aromatase inhibitors or fulvestrant in absence of visceral crisis, in addition to ensuring adequate ovarian function suppression in pre/peri-menopausal women. Aromatase inhibitors and fulvestrant seem to be superior. Resistance to such agents is increasing, mostly attributed to genetic and molecular changes. Multiple modalities are addressed to overcome such resistance including use of CKD4/6 inhibitors,...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractHuman breast cancer is a heterogeneous disease with numerous subtypes that have been defined through immunohistological, histological, and gene expression patterns. The diversity of breast cancer has made the study of its various underlying causes complex. To facilitate the examination of particular facets of breast cancer, mouse models have been generated, ranging from carcinogen induced models to genetically engineered mice. While mouse models have been generated to mimic the initiating event, including p53 loss, BRCA loss, or overexpression of HER2 / Neu / erbB2, other genomic events are often not well character...
Source: Journal of Mammary Gland Biology and Neoplasia - Category: Cancer & Oncology Source Type: research
More News: Academies | Avastin | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Databases & Libraries | Erbitux | Genetics | Hematology | HER2 | Herceptin | Hormonal Therapy | Hormones | Laboratory Medicine | National Institutes of Health (NIH) | Physiology | Research | Science | Sweden Health | Texas University | Universities & Medical Training | Women